Effectiveness and Safety of EXTOR AmlodipineValsartan in Adults Newly Diagnosed with Hypertension in Pakistan

What this Trial Is About

Researchers are evaluating the effects of EXTOR, a fixed-dose combination of amlodipine and valsartan, in adults newly diagnosed with hypertension. This study focuses on patients in routine practice in Pakistan and aims to measure the medications impact on blood pressure control and quality of life over an 8-week period. EXTOR combines two commonly used blood pressure medications with different actions to better manage hypertension. Participants will receive EXTOR, which combines amlodipine a calcium channel blocker that relaxes blood vessels and valsartan an angiotensin receptor blocker that prevents vessel constriction in a single pill. The study tracks changes in systolic and diastolic blood pressure at 4 and 8 weeks, as well as patient satisfaction using a treatment questionnaire. Safety is monitored throughout the study for all subjects who take at least one dose. During the study, participants will undergo regular blood pressure measurements and complete questionnaires about their health-related quality of life and medication satisfaction. Researchers will review blood pressure changes and safety outcomes after 8 weeks. This observational study includes adults aged 18 to 70 years who have not previously been treated for hypertension. Participation will last at least 8 weeks, during which safety and effectiveness data will be collected.

Clinical Response of EXTOR (Amlodipine/Valsartan) in Newly Diagnosed Hypertensive Patients.